Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology
File(s)PDSsubmittion_WarfarinManuscript_2013.11.19.pdf (4.18 MB)
Accepted version
Author(s)
Type
Journal Article
Date Issued
2014-07-04
Date Acceptance
2014-06-03
Citation
Pharmacoepidemiology and Drug Safety, 2014, 23 (9), pp.974-983
ISSN
1099-1557
Publisher
Wiley
Start Page
974
End Page
983
Journal / Book Title
Pharmacoepidemiology and Drug Safety
Volume
23
Issue
9
Copyright Statement
This is the peer reviewed version of the following article: Hallgreen C. E., van den Ham H. A., Mt-Isa S., Ashworth S., Hermann R., Hobbiger S., Luciani D., Micaleff A., Thomson A., Wang N., Tjeerd P. van S., Downey G., Hirsch I., Hockley K., Juhaeri J., Metcalf M., Mwangi J., Nixon R., Peters R., Stoeckert I., Waddingham E., Tzoulaki I., Ashby D. and Wise L. (2014), Benefit–risk assessment in a post-market setting: a case study integrating real-life experience into benefit–risk methodology, Pharmacoepidemiology and Drug Safety, 23, pages 974–983, doi: 10.1002/pds.3676, which has been published in final form at [https://dx.doi.org/10.1002/pds.3676]. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000341584200011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
benefit-risk
decision making
medicines
qualitative
quantitative
warfarin
pharmacoepidemiology
NONRHEUMATIC ATRIAL-FIBRILLATION
STROKE PREVENTION
TRIALS TRANSLATE
WARFARIN
ANTICOAGULATION
DABIGATRAN
EFFICACY
THERAPY
Publication Status
Published